Medical Oncology

Her2-negative breast cancer

Questions discussed in this category

Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?

PFS curves appear similar between the AKT-altered vs overall study population in the trial publication. Is there any additional information available ...

3 Answers available

What is your approach to treatment in hormone receptor positive, HER2 negative (0 IHC) metastatic breast cancer with ERBB2 gene amplification after progression on AI and fulvestrant CDK4/6i with visceral crisis?

1 Answer available

Would you recommend adjuvant abemaciclib for ER+ HER2 neg inflammatory breast cancer who do not achieve pCR with neoadjuvant chemotherapy?

MONARCHE added an amendment to their protocol to exclude inflammatory breast cancer so they technically would not qualify for the trial though it's ha...

2 Answers available

Would a HER2 mutation on NGS of a biopsy of a breast cancer liver metastasis change your management if the met is HER2- by IHC with the initial localized disease being HER2+?

If NGS was positive would you treat with HER2 directed therapy? How, if at all, would you incorporate T-DXd into this treatment paradigm?

5 Answers available

How far can you dose reduce abemaciclib for a patient who is having toxicity at starting doses?

Can you use 50 mg BID if intolerant to 150 mg and 100 mg dosing? Any tips for side effect management to help patients stay on full duration?

6 Answers available

Does the magnitude of benefit with 2 years of adjuvant abemaciclib outweigh side effects, given that many patients will receive CDK 4/6 inhibitors at breast cancer recurrence, precluding OS benefits?

MonarchE shows statistically significant improvement in IDFS and DRFS, but the magnitude of absolute benefit is modest (3-year IDFS and DRFS rates = 5...

6 Answers available

Will you offer adjuvant abemaciclib to breast cancer patients with high Ki-67 who are unable to receive either neoadjuvant or adjuvant chemotherapy due to comorbidities or who decline chemotherapy?

Majority of patients on MonarchE received neoadjuvant/adjuvant chemo. Does the availability of abemaciclib impact your decision to offer chemo ...

4 Answers available

If you have a high risk HR+, BRCA+ breast cancer patient who qualifies for adjuvant olaparib and abemaciclib, which one would you give and why?

Would you ever consider using these in sequence?

4 Answers available

How and on which specimens will you perform Ki-67 testing in newly diagnosed breast cancer?

Should this be sent on initial biopsy or on surgical pathology? What if an initially high risk patient has good risk findings post-operatively?What ha...

4 Answers available

How do you incorporate oncotype Dx recurrence score when planning adjuvant CDK 4/6 inhibitor for high risk early stage HR+ breast cancer?

1 Answer available

How do you view the use of adjuvant CDK4/6 inhibitors overall given discordant results between MonarchE and PALLAS?

Are there factors to explain why MonarchE was a positive study and PALLAS was not?

4 Answers available

Would you offer adjuvant abemaciclib + an aromatase inhibitor to a patient with a local HR+HER- breast cancer reoccurrence while on tamoxifen that meets high-risk criteria?

High-risk criteria meaning >4 positive nodes and Ki67 >20%

3 Answers available